What is Inventiva?
Headquartered in France, Inventiva operates at the intersection of advanced medical research and commercial scalability. The company specializes in the discovery and development of innovative therapeutic candidates designed to address complex pathologies. Through a disciplined approach to drug development, Inventiva has established itself as a critical player in the European life sciences ecosystem, focusing on high-impact treatments that aim to redefine patient outcomes. Its market position is bolstered by a history of strategic partnerships and a commitment to rigorous clinical validation, ensuring that its therapeutic portfolio remains at the forefront of modern medicine.
How much funding has Inventiva raised?
Inventiva has raised a total of $542.6M across 6 funding rounds:
Other Financing Round
$16.4M
Stock Offering
$107.7M
Share Placement
$36.7M
Private Equity
$99.6M
Debt
$131M
Debt
$151.2M
Other Financing Round (2020): $16.4M with participation from Novo Holdings, BVF Partners L.P., NEA, and Sofinnova Partners
Stock Issuance/Offering (2020): $107.7M, investors not publicly disclosed
Share Placement (2023): $36.7M, investors not publicly disclosed
Private Equity (2024): $99.6M featuring BVF Partners, New Enterprise Associates, and Samsara BioCapital
Debt (2025): $131M, investors not publicly disclosed
Debt (2026): $151.2M with participation from Claret Capital Partners and BlackRock
Key Investors in Inventiva
BVF Partners
A San Francisco-based private investment partnership specializing in fundamentally-driven public biotechnology investments with a focus on long-term value creation.
New Enterprise Associates
A premier venture capital firm established in 1977, dedicated to partnering with entrepreneurs to build transformative businesses across various sectors.
Samsara BioCapital
A specialized investment firm that collaborates with scientists and drug developers to foster the next generation of therapeutic breakthroughs in the biopharmaceutical industry.
What's next for Inventiva?
With the recent injection of capital, Inventiva is poised to enter a critical phase of operational expansion and clinical advancement. The strategic allocation of these funds will likely prioritize the progression of its lead assets through late-stage clinical trials, while simultaneously strengthening its balance sheet to navigate the complexities of the global biopharmaceutical landscape. As the company continues to refine its therapeutic focus, stakeholders anticipate further milestones in its clinical pipeline, which could serve as catalysts for long-term value creation and potential commercialization efforts in key international markets.
See full Inventiva company page
